Advertisement
News
Subscribe to MDT Magazine News

About the CDRH Inspections Database(2)

September 30, 2010 12:31 pm | by U.S. Food & Drug Administration | Comments

The CDRH Inspections Database1 provides information about medical device inspections that were the responsibility of CDRH from 2008 to the present.

TOPICS:

About the CDRH Inspections Database

September 30, 2010 12:30 pm | Comments

The CDRH Inspections Database1 provides information about medical device inspections that were the responsibility of CDRH from 2008 to the present.

USDA awards enhance the nutritional quality of food aid products

September 30, 2010 10:35 am | by EurekAlert | Comments

(United States Department of Agriculture -- Research, Education and Economics) The USDA's National Institute of Food and Agriculture awarded nearly $3.8 million to develop healthier food products for humanitarian assistance programs.

TOPICS:
Advertisement

Maine's Bigelow Laboratory gets $9M building grant

September 30, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | Comments

The U.S. Commerce Department’s National Institute of Standards and Technology has awarded a $9.1 million grant for a new Center for Ocean Health at Bigelow Laboratory for Ocean Sciences in West Boothbay Harbor, Maine.

Acton Pharmaceuticals raises $14M funding round

September 30, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Acton Pharmaceuticals Inc., a respiratory therapeutics firm in Marlborough, has raised $14.2 million from an offering of Series A-1 convertible preferred stock, according to a regulatory filing.

Aveo regains rights to cancer target from Merck

September 30, 2010 10:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Aveo Pharmaceuticals Inc. has regained development and commercialization rights to AV-299, a drug target being tested to treat non-small cell lung cancer, from Merck subsidiary Schering Corp.

Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

VIENNA, Sept. 30 /- Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales,...

TOPICS:

BioSpace Showcases Southern California's Growing Life Science Region

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

DENVER, Sept. 30 /- BioSpace has promoted biotechnology, pharmaceutical and medical device industries in San Diego and Southern California for more than a decade. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) (Logo:...

TOPICS:
Advertisement

Largest Study of Melanoma in US Hispanics Reveals California Population in Need of Targeted Prevention Efforts

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

FREMONT, Calif., Sept. 30 /- Scientists at the Cancer Prevention Institute of California (CPIC) , Stanford University, and the University of Southern California/Keck School of Medicine have found that while Hispanics have much lower risks of developing melanoma than non-Hispanic whites in...

TOPICS:

Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomat...

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

BURLINGTON, Mass., Sept. 30 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than...

TOPICS:

Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

BRUSSELS, Sept. 30 /- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented this week at the 2nd...

TOPICS:

Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites

September 30, 2010 10:33 am | by Bio-Medicine.Org | Comments

RESEARCH TRIANGLE PARK, N.C., Sept. 30 /- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization....

TOPICS:

New Study Reveals Collagenase SANTYL® Ointment More Effective Than Hydrogel Dressing for Pressure Ulcer Debridement

September 30, 2010 10:32 am | by Bio-Medicine.Org | Comments

FORT WORTH, Texas, Sept. 30 /- Healthpoint today announced that the results of a new study conducted by Catherine T. Milne APRN, MSN, CWOCN, BC-ANP, will be presented on Thursday, September 30, 2010 at 7:15pm (Eastern) at the Healthpoint booth (#110) during the 25th Annual Clinical...

TOPICS:

Disparities 2010: Interview with Rep. Elijah Cummings (D-Md.)

September 30, 2010 10:32 am | by AACR | Comments

Listen to Rep. Cummings discuss cancer health disparities with the American Association for Cancer Research.

TOPICS:

Disparities 2010: Interview with Deborah M. Smith, M.D., M.P.H.

September 30, 2010 10:32 am | by AACR | Comments

Listen to Dr. Smith as she speaks with the American Association for Cancer Research on the issue of cancer health disparities.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading